UPDATE: Raymond James Starts Corbus Pharmaceuticals (CRBP) at Outperform

---

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

---

(Updated - January 19, 2018 5:46 AM EST)

(updated to add analyst comment)

Raymond James initiates coverage on Corbus Pharmaceuticals (NASDAQ: CRBP) with a Outperform rating and a price target of $24.00.

ANalyst Laura Chico comments "In the three years since its IPO, Corbus Pharmaceuticals has diligently advanced its wholly-owned, lead asset lenabasum to pivotal studies in systemic sclerosis (SSc), with efforts also progressing in dermatomyositis (DM) and cystic fibrosis (CF). To date, we think data supports advancement, particularly when we consider the unmet need left by current therapies. Overall, recent non-dilutive funding from CFF and NIH provides important validation for Corbus."

For an analyst ratings summary and ratings history on Corbus Pharmaceuticals click here. For more ratings news on Corbus Pharmaceuticals click here.

Shares of Corbus Pharmaceuticals closed at $7.95 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UPDATE: Morgan Stanley Upgrades Frontier Communications (FYBR) to Equalweight
• Bakkavor Group Plc. (BAKK:LN) PT Lowered to GBP1.10 at Berenberg
• Tharisa Plc (THS:LN) PT Lowered to GBP2.50 at Berenberg